论文部分内容阅读
本实验对50例卵巢粘液癌、10例交界性瘤、20例卵巢粘液店中EGFR（表皮生长因子受体）、neu癌基因、PCNA（增殖细胞核抗原）表达进行研究，观察其在卵巢癌、交界性肿瘤、良性瘤的表达率，并采用半定量的ABC免疫组化方法研究不同强度表达与病理分化、临床分期、预后的关系，得到初步结果．EGFR在粘液癌表达54％，交界瘤40％，粘液瘤1096，其表达率与预后呈负相关，与病理分化、临床分期无明显相关住．neu在卵巢粘液癌中表达48％，其阳性表达车及表达强度与预后和病理分化有关。PC－NA在粘液癌中表达46％，交界瘤中30％，良性瘤10％，其表达强度与预后清理分化有关．结果表明EGFR、neu、PCNA与卵巢上皮癌预后有相关性，neu、PCNA与病理分化也有一定相关性．可能成为判断病理分化、临床预后的指标。
In this study, EGFR (epidermal growth factor receptor), neu oncogene, PCNA (proliferating cell nuclear antigen) expression in 50 cases of ovarian mucinous carcinoma, 10 cases of borderline tumor and 20 cases of ovarian mucous store were studied in ovarian cancer, Borderline tumors and benign tumors. The semi-quantitative ABC immunohistochemical method was used to study the relationship between different intensity expressions and pathological differentiation, clinical stage and prognosis, and the preliminary results were obtained. The expression of EGFR was 54% in mucinous carcinoma, 40% in borderline tumor and 1096 in myxoma. The expression rate of EGFR was negatively correlated with prognosis, but not with pathological differentiation and clinical stage. neu was expressed in 48% of ovarian mucinous carcinomas. The expression of neu was correlated with the prognosis and pathological differentiation. The expression of PC-NA was 46% in mucinous carcinoma, 30% in borderline tumor and 10% in benign tumor. The expression intensity of PCNA was related to the prognosis and differentiation. The results showed that EGFR, neu, PCNA and epithelial ovarian cancer prognosis are related, neu, PCNA and pathological differentiation are also related. May be to determine the pathological differentiation, clinical prognosis indicators.